Clovis Oncology, Inc. Contracts & Agreements
107 Contracts & Agreements
- Business Finance (29 contracts)
- Business Operations (18)
- Human Resources (15)
- Uncategorized (45)
- Asset Purchase Agreement, dated as of April 5, 2023, by and between Clovis Oncology, Inc. and pharma& Schweiz GmbH (Filed With SEC on April 6, 2023)
- Secured Superpriority Debtor-In-Possession Financing Agreement, dated as of January 6, 2023, by and among the Company, as borrower, Clovis Ireland and Clovis UK, as guarantors,... (Filed With SEC on January 12, 2023)
- Pledge and Security Agreement, dated as of January 6, 2023, by and among the Company certain subsidiaries of the Company, as grantors, and the Administrative Agent (Filed With SEC on January 12, 2023)
- DIP Term Sheet (Filed With SEC on December 19, 2022)
- Purchase and Assignment Agreement, dated as of December 11, 2022, by and between Clovis Oncology, Inc. and Novartis Innovative Therapies AG (Filed With SEC on December 13, 2022)
- Superpriority Debtor-In-Possession Facility Commitment Letter, dated as of December 11, 2022, by and among Clovis Oncology, Inc. and the Commitment Parties (Filed With SEC on December 13, 2022)
- Distribution Agreement, dated August 16, 2021, by and among Clovis Oncology, Inc., J.P. Morgan Securities LLC and BofA Securities, Inc (Filed With SEC on August 16, 2021)
- Clovis Oncology, Inc. Amended and Restated 2020 Stock Incentive Plan (Filed With SEC on August 4, 2021)
- Clovis Oncology, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on August 4, 2021)
- Indemnification Agreement, dated as of July 12, 2021, by and between Clovis Oncology, Inc. and Ronit Simantov (Filed With SEC on July 13, 2021)
- Distribution Agreement, dated May 17, 2021, by and among Clovis Oncology, Inc., J.P. Morgan Securities LLC and BofA Securities, Inc (Filed With SEC on May 17, 2021)
- Employment Agreement, dated as of May 4, 2021, by and between Clovis Oncology, Inc. and Thomas C. Harding (Filed With SEC on May 5, 2021)
- Indemnification Agreement, dated as of May 3, 2021, by and between Clovis Oncology, Inc. and Thomas C. Harding (Filed With SEC on May 5, 2021)
- License and Collaboration Agreement, dated September 20, 2019 by and between 3B Pharmaceuticals GmbH and Clovis Oncology, Inc (Filed With SEC on February 25, 2021)
- Indenture, dated as of November 17, 2020, by and between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, relating to the New 2024 Notes (Filed With SEC on November 17, 2020)
- Form of Indenture, to be entered into by and between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, relating to the New 2024 Notes (Filed With SEC on November 5, 2020)
- Form of Exchange and Purchase Agreement (Filed With SEC on November 5, 2020)
- Clovis Oncology, Inc. 2020 Stock Incentive Plan (Filed With SEC on August 7, 2020)
- Form of Clovis Oncology, Inc. 2020 Stock Incentive Plan Option Grant Notice and Agreement (Filed With SEC on June 4, 2020)
- Form of Clovis Oncology, Inc. 2020 Stock Incentive Plan Restricted Stock Unit Grant Notice and Agreement (Filed With SEC on June 4, 2020)
- Underwriting Agreement, dated May 18, 2020 (Filed With SEC on May 21, 2020)
- Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 26, 2020)
- Indenture, dated as of August 13, 2019, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (Filed With SEC on August 13, 2019)
- Pledge and Security Agreement, dated as of May 1, 2019 among each of the Grantors party thereto and the Administrative Agent party thereto (Filed With SEC on May 2, 2019)
- Financing Agreement, dated as of May 1, 2019 among Clovis Oncology, Inc. (the Company), certain subsidiaries of the Company named therein, as Guarantors, the Lenders from time to... (Filed With SEC on May 2, 2019)
- Amendment to Employment Agreement, by and between Clovis Oncology, Inc. and Patrick Mahaffy, dated March 14, 2019 (Filed With SEC on March 14, 2019)
- Amendment to Employment Agreement, by and between Clovis Oncology, Inc. and Daniel Muehl, dated March 14, 2019 (Filed With SEC on March 14, 2019)
- Amendment to Employment Agreement, by and between Clovis Oncology, Inc. and Gillian Ivers-Read, dated March 14, 2019 (Filed With SEC on March 14, 2019)
- Amendment to Employment Agreement, by and between Clovis Oncology, Inc. and Paul Gross, dated March 14, 2019 (Filed With SEC on March 14, 2019)
- Amended and Restated Employment Agreement, dated as of February 27, 2019, by and between Clovis Oncology, Inc. and Clovis Oncology UK Limited and Lindsey Rolfe (Filed With SEC on February 28, 2019)
- Employment Agreement, dated as of July 6, 2017, between Clovis Oncology, Inc. and Paul Gross (Filed With SEC on February 28, 2019)
- Indemnification Agreement, dated as of September 9, 2016, between Clovis Oncology, Inc. and Paul Gross (Filed With SEC on February 28, 2019)
- Indemnification Agreement, dated as of October 11, 2018, by and between Clovis Oncology, Inc. and Robert W. Azelby (Filed With SEC on October 12, 2018)
- Indemnification Agreement, dated as of October 11, 2018, by and between Clovis Oncology, Inc. and Richard A. Fair (Filed With SEC on October 12, 2018)
- Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan, as amended (Filed With SEC on August 2, 2018)
- Underwriting Agreement, dated April 16, 2018 (Filed With SEC on April 19, 2018)
- Underwriting Agreement, dated April 16, 2018 (Filed With SEC on April 19, 2018)
- Indenture, dated April 19, 2018 (Filed With SEC on April 19, 2018)
- First Supplemental Indenture, dated April 19, 2018 (Filed With SEC on April 19, 2018)
- EMPLOYMENT AGREEMENT (Filed With SEC on July 7, 2017)
- CLOVIS ONCOLOGY, INC. 3,409,091Shares of Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on June 26, 2017)
- Strata Trial Collaboration Agreement (Filed With SEC on May 4, 2017)
- RESTRICTED STOCK UNIT GRANT NOTICE AND AGREEMENT (Filed With SEC on February 23, 2017)
- Manufacturing Services Agreement (the “Agreement”) (Filed With SEC on February 23, 2017)
- CLOVIS ONCOLOGY, INC. 5,000,000Shares of Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on January 9, 2017)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. First Amendment to License Agreement between Clovis... (Filed With SEC on November 4, 2016)
- CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on April 1, 2016)
- CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on February 29, 2016)
- EMPLOYMENT AGREEMENT (Filed With SEC on February 29, 2016)
- CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on February 29, 2016)
- EMPLOYMENT AGREEMENT (Filed With SEC on February 29, 2016)
- CLOVIS ONCOLOGY, INC. (Filed With SEC on August 12, 2015)
- CLOVISONCOLOGY, INC. 3,525,641 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on July 14, 2015)
- CLOVISONCOLOGY, INC. AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of September 9, 2014 2.50% Convertible Senior Notes due 2021 TABLE OF... (Filed With SEC on September 9, 2014)
- CLOVISONCOLOGY, INC. 2,000,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on December 9, 2013)
- STOCK PURCHASE AGREEMENT by and among CLOVISONCOLOGY, INC., EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A., THE SELLERS LISTED ON EXHIBIT A HERETO, and SOFINNOVA CAPITALV FCPR, as the... (Filed With SEC on November 19, 2013)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 19, 2013)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. Development and Commercialization Agreement by and... (Filed With SEC on November 19, 2013)
- COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on November 19, 2013)
- CLOVIS ONCOLOGY, INC. 3,333,334 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on June 17, 2013)
- CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on June 14, 2013)
- CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on June 14, 2013)
- CLOVIS ONCOLOGY, INC. [ ] Shares of Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on March 30, 2012)
- EMPLOYMENT AGREEMENT (Filed With SEC on March 23, 2012)
- CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on March 23, 2012)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on October 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on October 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on October 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on October 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on October 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on October 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on October 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on October 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on October 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on October 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on August 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on August 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on August 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on August 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments (Filed With SEC on August 31, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on August 5, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on August 5, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
- Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of... (Filed With SEC on June 23, 2011)
